REGN
Regeneron Pharmaceuticals, Inc.
$794.19-1.48%
Price
- Market cap
- $81.64 billion
- P/E (TTM)
- 19.67
- EV/EBITDA
- 18.57
- 52W range
- $555.51 – $840.84
- Div yield
- 0.46%
- Volume
- 443.9K
- Sector
- Healthcare
Regeneron Pharmaceuticals, Inc. (REGN) last closed at $794.19, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for REGN, covered for search and blurred for visitors.
Performance
- 1D-0.22%
- 5D+3.51%
- 1M+0.22%
- 3M+23.59%
- 6M+7.91%
- 1Y+39.69%
- 5Y+47.26%
Financials
Over the latest four reported periods ending June 30, 2026, Regeneron Pharmaceuticals, Inc. reported revenue of $15.53 billion.
The prior window totaled $14.21 billion, so the latest window is higher than that stretch.
Operating cash flow in the latest window was $4.68 billion.
Free cash flow in the latest window was $3.76 billion.
These amounts are taken from Regeneron Pharmaceuticals, Inc.'s SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.
A few ratios from those statements: Profitability: ROE 4.1% (38 of 100). Leverage: D/E 0.06× (97 of 100). Cash generation: FCF margin 24.2% (48 of 100). Net margin: 30.2% (76 of 100). Liquidity: Current 3.34× (100 of 100).
Cash Flow
Margins
Valuation
- P/E (TTM)
- 19.67
- P/S (TTM)
- 5.26
- EV/EBITDA
- 18.57
Insights
Finorify has not written notes for REGN in this snapshot.
Read the live analysis in Finorify
Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.
Open REGN in Finorify